We showed previously that cruciferous vegetable constituent benzyl isothiocyanate (BITC) inhibits growth of cultured and xenografted human breast cancer cells, and suppresses mammary cancer development in a transgenic mouse model. We now demonstrate, for the first time, that BITC inhibits epithelial-to-mesenchymal transition (EMT) in human breast cancer cells. Exposure of estrogen-independent MDA-MB-231 and estrogen-responsive MCF-7 human breast cancer cell lines and a pancreatic cancer cell line (PL-45) to BITC resulted in upregulation of epithelial markers (e.g., E-cadherin and/or occludin) with a concomitant decrease in protein levels of mesenchymal markers, including vimentin, fibronectin, snail, and/or c-met. The BITC-mediated induction of E-cadherin protein was accompanied by an increase in its transcription, whereas BITC-treated MDA-MB-231 cells exhibited suppression of vimentin, snail, and slug mRNA levels. Experimental EMT induced by exposure to transforming growth factor ȕ1 (TGFȕ) and tumor necrosis factor-Į (TNFĮ) or Rb knockdown in a spontaneously immortalized non-tumorigenic human mammary epithelial cell line (MCF-10A) was also partially reversed by BITC treatment. The TGFȕ/TNFĮ-induced migration of MCF-10A cells was inhibited in the presence of BITC, which was partially attenuated by RNA interference of Ecadherin. Inhibition of MDA-MB-231 xenograft growth in vivo in female athymic mice by BITC administration was associated with an increase in protein level of E-cadherin and suppression of vimentin and fibronectin protein expression. In conclusion, the present study reports a novel anticancer effect of BITC involving inhibition of EMT, a process triggered during progression of cancer to invasive state.
Introduction
Breast cancer is a serious public health concern for women worldwide (1, 2) . Despite remarkable progress towards screening efforts and unremitting advancement of targeted therapies, breast cancer is still a leading cause of cancer related deaths in women (1) (2) (3) (4) . A number of mammary cancer risk factors have been identified, including family history, LiFraumeni syndrome, atypical hyperplasia of the breast, late age at first full-term pregnancy, early menarche and late menopause (5) (6) (7) . Because many of the risk factors associated with mammary cancer development are not easily adjustable, other strategies for prevention of this dreadful disease are appealing to reduce disease-related cost, mortality, and morbidity for a large segment of female population. Prevention of breast cancer is feasible considering successful clinical applications of selective estrogen-receptor modulators, including tamoxifen and raloxifene (8) (9) (10) .
Unfortunately, this strategy is effective only against estrogen-receptor positive breast cancers and suffers from adverse side effects, including increased risk of uterine cancer, thromboembolism, and perimenopausal symptoms (8) (9) (10) . Discovery of agents efficacious for prevention of breast cancer regardless of the estrogen-receptor status is desired. Dietary plants have drawn increasing attention in recent years for the discovery of cancer preventive and therapeutic agents (11) (12) (13) .
Population-based case-control studies have documented an inverse association between intake of cruciferous vegetables and the risk breast cancer (14, 15) . For example, a case-control study involving >300 breast cancer cases and matched controls showed an inverse association between urinary levels of isothiocyanates (ITCs) as a biological measure of cruciferous vegetable intake and the risk of breast cancer (14) . Broccoli consumption was also found to be inversely associated with the risk of mammary cancer in premenopausal women (15) . Anticancer property of cruciferous vegetables is ascribed to organic ITCs, which are produced upon cutting or chewing of these vegetables (16) . Benzyl isothiocyanate (BITC) is one such ITC compound that appears promising for prevention of breast cancer based on our own work. We showed previously that administration of BITC in the diet (3 ȝmol BITC/g diet) inhibited mammary hyperplasia and carcinoma incidence and/or burden in MMTV-neu transgenic mice in association with suppression of cell proliferation, apoptosis induction, and tumor infiltration of T cells (17) . We also found that the growth of MDA-MB-231 human breast cancer cells implanted in female athymic mice was inhibited significantly by BITC administration (18) .
Cellular studies have provided novel insights into the mechanisms underlying anticancer effects of BITC (19) (20) (21) (22) (23) . For example, our own work has revealed that BITC treatment inhibits growth of cultured human breast cancer cells (MDA-MB-231 and MCF-7) by causing G 2 /M phase cell cycle arrest and p53-independent apoptotic cell death (19, 22, 23) . Noticeably, a spontaneously immortalized non-tumorigenic human mammary epithelial cell line (MCF-10A) is significantly more resistant to growth inhibition and apoptosis induction by BITC compared with breast cancer cells (19, 22) . Molecular circuitry of BITC-induced apoptosis involves production of reactive oxygen species due to inhibition of complex III of the mitochondrial respiratory chain (22) . The present study builds on these observations and demonstrates, for the first time, that BITC inhibits epithelial-mesenchymal transition (EMT), which is implicated in progression of cancers to invasive state (24) (25) (26) .
Materials and Methods

Reagents
BITC (purity >98%) was purchased from LKT Laboratories. Reagents for cell culture including medium, fetal bovine serum, and antibiotics were purchased from Invitrogen-Life
Technologies. Transforming growth factor-ȕ1 (TGFȕ) was from Calbiochem, and tumor necrosis 5 factor-Į (TNFĮ) was obtained from Sigma-Aldrich. Antibodies against E-cadherin and ȕ-catenin were purchased from BD Transduction Laboratories; anti-snail antibody was from Abgent; antibodies against vimentin and actin were from Sigma-Aldrich; anti-fibronectin and anti-c-met antibodies were from Santa Cruz Biotechnology; anti-Rb antibody was from Cell Signaling; antioccludin antibody was from Invitrogen-Life Technologies; and anti-p53 antibody was from Calbiochem. The vimentin antibody used for immunofluorescence microscopy was from Santa Cruz Biotechnology. Alexa Fluor 488-conjugated goat anti-mouse antibody and Alexa Fluor 568-conjugated donkey anti-goat antibodies were from Invitrogen-Life Technologies. E-cadherin promoter reporter construct was purchased from Addgene. E-cadherin-targeted small interfering RNA (siRNA) was from Ambion; Rb-targeted siRNA was from Thermo Fisher ScientificDharmacon, and a control non-specific siRNA was purchased from Qiagen.
Cell lines
The MDA-MB-231, MCF-7, MCF-10A, and PL-45 cell lines were obtained from the 6 treated cells and tumor tissues from control and BITC-treated mice were processed for immunoblotting as described by us previously (18, 19, 27) . Lysate proteins were resolved by sodium-dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membrane. After blocking with 5% non-fat dry milk in Tris-buffered saline containing 0.05% Tween-20, the membrane was incubated with the desired primary antibody for 1 hour at room temperature or overnight at 4ÛC. Immunoreactive bands were visualized by enhanced Chemiluminescence method. Densitometric quantitation was done using UN-SCAN-IT software version 5.1 (Silk Scientific Corporation, Orem, Utah, USA).
Immunocytochemical analysis for E-cadherin and vimentin
Cells (2.5×10
4 cells/mL) were cultured on coverslips, allowed to attach, and then exposed to DMSO (control), 2.5 ȝmol/L BITC, and/or a combination of 10 ng/mL each of TGFȕ and TNFĮ for specified time period. The cells were fixed with 2% paraformaldehyde for 1 hour, permeabilized with phosphate-buffered saline (PBS) containing 0.05% Triton X-100 for 10 minutes, and blocked with 0.5% bovine serum albumin in PBS for 1 hour at room temperature.
For single-antibody staining (E-cadherin and vimentin), the cells were incubated overnight with
anti-E-cadherin or anti-vimentin antibody at 4°C, washed with PBS, and incubated with Alexa
Fluor 568-conjugated secondary antibody (Molecular Probes) for 1 hour at room temperature.
For E-cadherin/actin double staining, the cells were incubated with E-cadherin antibody overnight at 4°C, followed by extensive washing with PBS and incubation with Alexa Fluor 568-conjugated secondary antibody (Molecular Probes) for 1 hour at room temperature. A monoclonal anti-actin antibody was then added followed by 2 hours of incubation at room 
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were stained with DAPI (10 ng/mL; 5 minutes at room temperature). Cells were washed twice with PBS, mounted, and examined under a Leica DC300F microscope.
Reverse transcription-PCR (RT-PCR)
Total RNA was prepared from DMSO-treated control and BITC-treated MDA-MB-231 or MCF-7 cells using RNeasy kit (Invitrogen) and reverse transcribed with reverse transcriptase and oligo(dT) 20 and 0.8 ȝg of pRL-CMV plasmid using Fugene6. Twenty-four hours after transfection, the cells were treated with DMSO or BITC for 8 or 16 hours. Luciferase activity was determined using dual-luciferase reporter assay kit (Promega).
Migration assay
Effect of BITC treatment on MCF-10A cell migration was determined using Transwell Life Technologies) and then transfected with 150 nmol/L E-cadherin-targeted siRNA or Rbtargeted siRNA or control siRNA using OligofectAMINE. Forty-eight hours after transfection, the cells were treated with DMSO, BITC and/or TGFȕ and TNFĮ (10 ng/mL of each) for 24 hours. The cells were then collected and processed for immunoblotting and migration assay.
Immunohistochemistry for E-cadherin and vimentin in MDA-MB-231 xenografts
We have shown previously that BITC administration significantly retards growth of MDA-MB-231 cells implanted in female athymic mice (18) . We used tumor tissues from the same study to determine the effect of BITC administration on expression of E-cadherin and vimentin by immunohistochemistry. Representative tumor sections from control and BITCtreated mice were processed for immunohistochemical analysis of E-cadherin and vimentin essentially as described by us previously for other proteins (17, 18, 23) .
Results
BITC up-regulated E-cadherin protein expression in cancer cells
Loss of expression of epithelial adherens junction proteins (e.g., E-cadherin and occludin) with a concomitant gain of mesenchymal marker expression (e.g., vimentin, fibronectin) is a biochemical hallmark of EMT (24) (25) (26) (28) (29) (30) . Loss of E-cadherin expression is associated with increased invasion in breast cancer cells (25, 26) . Expression of E-cadherin is very low in the MDA-MB-231 cell line, which is a highly invasive "basal B" type and estrogen-independent fibroblastic human breast cancer cell line with stellate morphology (31) . Initially, we used this cell line to test whether BITC treatment affected EMT. As can be seen in marker vimentin especially at the 2.5 μmol/L concentration (Fig. 1A) . The c-met along with Ecadherin constitutes a marker signature associated with angiogenic and lymphangiogenic factors in breast ductal carcinoma in situ (32) . The c-met expression inversely correlates with E-cadherin expression (32) . We observed a decrease in the level of c-met protein in MDA-MB-231 cells after treatment with 2.5 ȝmol/L BITC for 16 hours, which was somewhat reversible at the 24 hour time point (Fig. 1A) . In addition to regulating canonical Wnt signaling pathway, ȕ-catenin also serves as a component of adherens junctions and links E-cadherin to the cytoskeleton (33).
Expression of ȕ-catenin was not affected by BITC treatment (results not shown). We also determined the effect of BITC treatment on protein level of snail, a transcription factor that functions as a repressor of E-cadherin gene in epithelial tumor cells (34) . Expression of snail was also reduced in MDA-MB-231 cells after treatment with 2.5 ȝmol/L BITC at both 16 and 24 hour time points (Fig. 1A) .
Next, we questioned if the BITC-mediated induction of E-cadherin protein was unique to the "basal" type breast cancer cells. We addressed this question using MCF-7 and PL-45 cells.
The MCF-7 cell line is a well-accepted representative of estrogen-receptor positive "luminal" type breast cancer (31) . Unlike MDA-MB-231 cells, the MCF-7 cell line exhibits epithelial phenotype with high expression of E-cadherin and occludin (31) . Expression of mesenchymal marker vimentin is not detectable in MCF-7 cells (31) . In contrast to the MDA-MB-231 cell line, expression of E-cadherin and occludin proteins was only modestly increased by BITC treatment in the MCF-7 cell line (Fig. 1B) . Exposure of a highly invasive pancreatic cancer cell line (PL- (Fig. 1C) . We were unable to detect vimentin protein expression in this cell line. (Fig. 1D) .
We performed immunocytochemistry to confirm results of the immunoblotting regarding effect of BITC treatment on protein levels of E-cadherin and vimentin using MDA-MB-231 cells.
Constitutive expression of E-cadherin (red fluorescence) was very weak in DMSO-treated control MDA-MB-231 cells ( Fig. 2A) . Immunocytochemical staining for E-cadherin was clearly visible around DAPI stained nuclei in MDA-MB-231 cells following 24 hour exposure to 2.5 ȝmol/L BITC ( Fig. 2A) . Noticeably, the BITC-mediated induction of E-cadherin protein expression was evident in both apoptotic (marked by an arrow in Fig. 2A ) and non-apoptotic cells (marked by an arrowhead in Fig. 2A ). Constitutive expression of vimentin protein, characterized by filamentous microtentacle like protrusions, was clearly visible in DMSO-treated control MDA-MB-231 cells (Fig. 2B) . Expression of vimentin protein was markedly suppressed after 24 hour treatment of MDA-MB-231 cells with 2.5 ȝmol/L BITC in association (Fig. 2B) .
The BITC treatment also resulted in disruption of the vimentin network (Fig. 2B) .
BITC treatment increased E-cadherin transcription in breast cancer cells
The BITC treatment caused an increase in the levels of E-cadherin mRNA in MDA-MB-231 and MCF-7 cells at both 8 and 16 hour time points (Fig. 2C) . Consistent with the immunoblotting results (Fig. 1) , the BITC-mediated increase in E-cadherin mRNA expression (Fig. 2C) . These results indicate cell line-specific differences in BITC-mediated induction of Ecadherin mRNA at least in breast cancer cells.
Luciferase activity in MDA-MB-231 cells transiently transfected with an E-cadherin
promoter reporter construct (E-cadherin promoter sequence from -108 to +125) was also significantly increased upon treatment with 2.5 ȝmol/L BITC in comparison with DMSO-treated control at both 8 and 16 hour time points (Fig. 2D) . These results indicated that BITC treatment increased transcription of E-cadherin in both MDA-MB-231 and MCF-7 cells.
Reversal of TGF-ȕ/TNF-Į-induced EMT by BITC in MCF-10A cells
We used an experimental system involving TGFȕ/TNFĮ (10 ng/mL of each) and MCF-10A cells to confirm BITC-mediated inhibition of EMT. The MCF-10A cell line, which was isolated from fibrocystic breast disease and spontaneously immortalized, is non-tumorigenic and widely used as a representative normal mammary epithelial cell line. The DMSO-treated control MCF-10A cells exhibited round and well-packed cobblestone appearance, a morphological feature of epithelial cells (Fig. 3A) . Morphology of the MCF-10A cells was altered by a 24-hour exposure to known EMT inducers TGFȕ/TNFĮ with a large fraction of cells exhibiting mesenchymal phenotype characterized by spindle shaped morphology with cell scattering and loss of cell-cell contact (Fig. 3A) . The BITC treatment alone did not have an appreciable effect on MCF-10A morphology. The TGFȕ/TNFĮ-induced EMT was partially reversible in the presence of BITC with restoration of cell-cell contact (Fig. 3A) .
Next, immunoblotting was done using lysates from TGFȕ/TNFĮ and/or BITC-treated cells to confirm reversal of EMT by BITC. As shown in Figure 3B (Fig. 3C) , which are implicated in EMT (35, 36) . The TGFȕ/TNFĮ-mediated suppression of p53 and Rb protein expression was also fully (p53) or partially reversible (Rb) in the presence of BITC (Fig.   3C ). Fig. S1A ) was accompanied by suppression of E-cadherin (60% decrease) and occludin protein expression (90% decrease) with a concomitant upregulation of fibronectin protein expression (1.5-fold increase) (Supplemental Fig. S1B ). These effects mediated by Rb protein knockdown were partially reversible in the presence of BITC (Supplemental Fig. S1B ). Another phenotype associated with Rb protein knockdown was increased migratory potential of MCF-10A cells (Supplemental Fig. S1C ). The MCF-10A cell migration was markedly reduced in the presence of BITC regardless of Rb expression status (Supplemental Fig. S1C ). Together, these results indicated that BITC cooperated with Rb to inhibit EMT in our model.
BITC treatment inhibited TGFȕ/TNFĮ induced cell migration
We designed experiments to determine anti-migratory effect of BITC in TGFȕ/TNFĮ stimulated MCF-10A cells. As shown in (Fig. 4B) . Protein level of E-cadherin was reduced by over 98% in MCF-10A cells transfected with an E-cadherin-specific siRNA (Fig. 4B ). Similar to un-transfected cells (Fig. 4A ) migratory potential of control siRNAtransfected MCF-10A cells was increased markedly in the presence of 10 ng/mL each of TGFȕ and TNFĮ (Fig. 4C) . Quantitation of migrated cells was not possible in this experiment due to cell clumping. Knockdown of E-cadherin protein also caused a marked increase in migration capability of MCF-10A cells even in the absence of TGFȕ and TNFĮ (Fig. 4C) . Migration ability of E-cadherin-depleted MCF-10A cells was only slightly increased in the presence of TGFȕ and TNFĮ in comparison with control siRNA transfected cells (Fig. 4C) . Nevertheless, BITC treatment exhibited significant inhibitory effect against migration in E-cadherin siRNAtransfected MCF-10A cells regardless of the TGFȕ and TNFĮ stimulation.
Formation of adherens junctions is important for maintenance of the epithelial phenotype (24) (25) (26) . Expression of E-cadherin protein was decreased in TGFȕ and TNFĮ-treated MCF-10A cells leading to loss of cell-cell contact and appearance of lamellipodia in some cells (identified by arrows). Moreover, when the cells were co-treated with 2.5 μmol/L BITC and 10 ng/mL each of TGFȕ and TNFĮ, a reversion to epithelial phenotype was discernible as evidenced by an increase in E-cadherin staining and emergence of cell-cell contact (Fig. 5) .
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In vivo effect of BITC administration on EMT markers in MDA-MB-231 xenografts
We have shown previously that growth of MDA-MB-231 xenografts in female athymic mice is inhibited significantly by i.p. BITC administration (2.5 and 7.5 ȝmol BITC/mouse, five times per week) (18) . For example, 50 d after tumor cell injection the average tumor volume in control mice (1581 ± 240 mm 3 ) was about 2.5-to 3-fold higher compared with BITC-treated mice (18) . We used tumor tissues from the same experiment to determine the effect of BITC administration on expression of EMT markers. E-cadherin protein expression was very low in the tumors from control mice (Fig. 6A) . The BITC administration dose-dependently caused upregulation of E-cadherin protein expression in MDA-MB-231 xenografts (Fig. 6A) . Expression of vimentin protein was markedly decreased in MDA-MB-231 tumors from BITC-treated mice compared with those of control mice (Fig. 6B) . Results of immunohistochemical analyses were confirmed by Western blotting using tumor supernatants from control and 7.5 ȝmol BITC-treated mice (Fig. 6C) . Tumors from the BITC-treated mice exhibited increased expression of Ecadherin protein compared with control. In agreement with cellular data, MDA-MB-231 tumors from BITC-treated mice revealed a marked decrease in protein levels of fibronectin and vimentin in comparison with those of control mice (Fig. 6C) . Together, these results provided in vivo evidence for BITC-mediated suppression of EMT.
Discussion
The EMT is essential for normal physiological processes such as embryonic development, tissue remodeling, and wound healing (37) . During EMT, epithelial phenotype characterized by tight cell-cell junctions and polarity changes to a mesenchymal phenotype typified by disruption of the cell-cell contact with conversion to fibroblastic morphology and increased motility (37) .
Moreover, the EMT assumes a central place in pathogenesis of aggressive cancers (33) . For Adherens junctions are important for maintenance of epithelial integrity (33, 37, 43) . The E-cadherin is regarded as a tumor suppressor because of its role in maintenance of epithelial phenotype (44) (45) (46) . The E-cadherin is frequently down-regulated during cancer progression and correlates with poor prognosis (45) . In mesenchymal cells, E-box elements located within 108 bp of the 5'-region of the E-cadherin promoter are responsible for its transcriptional repression by Snail and other transcriptional factors (34, 47) . Because BITC treatment suppresses expression of snail and slug mRNA and increases transcription of E-cadherin, it is reasonable to conclude that BITC-mediated induction of E-cadherin involves E-box elements. Further studies are needed to test this hypothesis. During EMT, cells undergo cytoskeletal reorganization into actin stress fibers to acquire spindle shape morphology and increased cellular motility (29, 33) . The TGFȕ/TNFĮ treated MCF-10A cells display higher propensity for migration and cytoskeleton remodeling with actin reorganization. The BITC treatment is able to inhibit cytoskeletal remodeling and formation of actin stress fibers leading to suppression of TGFȕ/TNFĮ-stimulated cell migration.
In conclusion, the present study is the first published report to document inhibition of EMT by BITC that is characterized by up-regulation of adherens junction proteins (E-cadherin and occludin), down-regulation of mesenchymal markers such as vimentin and fibronectin, and suppression of transcriptional repressors of E-cadherin (snail and slug). GAPDH was used as a loading control. Each experiment was repeated at least twice and representative data from one such experiment are shown. 
